The article argues for rigorously validated quantitative protein biomarkers and outlines the analytical and clinical steps needed to translate proteomic discoveries into practice. This reflects a central challenge for Eliptica: turning large-scale mass-spectrometry measurements into robust biological signals that can support clinically meaningful prediction and decision-making.